Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 4, 2010, Pages 467-476

  Hernandez Pastor, Luis Javier ^a   Ortega, Ana ^a   García Layana, Alfredo ^a   Giráldez, Joaquín ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Age related macular degeneration; Cost effectiveness; Cost utility; Pegaptanib; Ranibizumab

Indexed keywords

PEGAPTANIB; RANIBIZUMAB;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; ENDOPHTHALMITIS; HEALTH CARE COST; HUMAN; LENS DISEASE; LENS INJURY; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SENSITIVITY ANALYSIS; SPAIN;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; MACULAR DEGENERATION; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; SPAIN; VISUAL ACUITY;

EID: 77949267120     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1156-9     Document Type: Article

References (39)

1. S Resnikoff D Pascolini D Etya'ale I Kocur R Pararajasegaram G Pokharel S Mariotti 2004 Global data on visual impairment in the year 2002 Bull World Health Organ 82 844 849 15640920
2. RD Jager WF Mieler JW Miller 2008 Age-related macular degeneration N Engl J Med 358 2606 2617 10.1056/NEJMra0801537 1:CAS:528:DC%2BD1cXnt1WmtLc%3D 18550876 (Pubitemid 351831361)
3. MS Ip IU Scott GC Brown MM Brown AC Ho SS Huang FM Recchia 2008 Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology Ophthalmology 115 1837 1846 10.1016/j.ophtha.2008.08.012 18929163
4. ES Gragoudas AP Adamis ET Cunningham Jr M Feinsod DR Guyer 2004 Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2805 2816 10.1056/NEJMoa042760 1:CAS:528:DC%2BD2MXhslyntw%3D%3D 15625332 (Pubitemid 40051904)
5. U Chakravarthy AP Adamis ET Cunningham Jr M Goldbaum DR Guyer B Katz M Patel 2006 Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration Ophthalmology 113 1508 e1501 e1525
6. PJ Rosenfeld DM Brown JS Heier DS Boyer PK Kaiser CY Chung RY Kim 2006 Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419 1431 10.1056/NEJMoa054481 1:CAS:528:DC%2BD28XhtVGgtr3M 17021318 (Pubitemid 44511557)
7. DM Brown PK Kaiser M Michels G Soubrane JS Heier RY Kim JP Sy S Schneider 2006 Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432 1444 10.1056/NEJMoa062655 1:CAS:528:DC%2BD28XhtVGgtrrI 17021319 (Pubitemid 44511558)
8. ZF Bashshur A Bazarbachi A Schakal ZA Haddad CP El Haibi BN Noureddin 2006 Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration Am J Ophthalmol 142 1 9 10.1016/j.ajo.2006.02.037 1:CAS:528:DC%2BD28Xms1GktLg%3D 16815245 (Pubitemid 43946791)
9. RF Spaide K Laud HF Fine JM Klancnik Jr CB Meyerle LA Yannuzzi J Sorenson J Slakter YL Fisher MJ Cooney 2006 Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 383 390 10.1097/00006982-200604000-00001 16603955 (Pubitemid 44197628)
10. RL Avery DJ Pieramici MD Rabena AA Castellarin MA Nasir MJ Giust 2006 Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 363-372 e365
11. JS Schouten EC La Heij CA Webers IJ Lundqvist F Hendrikse 2009 A systematic review on the effect of bevacizumab in exudative age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 247 1 11 10.1007/s00417-008-0952-y 1:CAS:528:DC%2BD1cXhtl2qtLjO 18843500
12. SS Lynch CM Cheng 2007 Bevacizumab for neovascular ocular diseases Ann Pharmacother 41 614 625 10.1345/aph.1H316 1:CAS:528:DC%2BD2sXltlOnsrs%3D 17355998 (Pubitemid 46625484)
13. ZF Bashshur ZA Haddad A Schakal RF Jaafar M Saab BN Noureddin 2008 Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study Am J Ophthalmol 145 249 256 10.1016/j.ajo.2007.09.031 1:CAS:528:DC%2BD1cXhtV2hsr8%3D 18067876
14. Comparison of AMD Treatments Trials (CATT): Lucentis - Avastin Trial. National Eye Institute. Available at: http://www.nei.nih.gov/CATT. Accesed: 23rd of June, 2009
15. GC Brown MM Brown HC Brown S Kindermann S Sharma 2007 A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration Ophthalmology 114 1170 1178 10.1016/j.ophtha.2006.09.019 17320964 (Pubitemid 46829369)
16. L Hernandez-Pastor A Ortega A Garcia-Layana J Giraldez 2008 Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration Clin Ther 30 2436 2451 10.1016/j.clinthera.2008.12.025 19167602
17. A Briggs M Sculpher 1998 An introduction to Markov modelling for economic evaluation Pharmacoeconomics 13 397 409 10.2165/00019053-199813040-00003 1:STN:280:DyaK1c3jvVKhsQ%3D%3D 10178664 (Pubitemid 28140699)
18. MJ Sculpher K Claxton M Drummond C McCabe 2006 Whither trial-based economic evaluation for health care decision making? Health Econ 15 677 687 10.1002/hec.1093 16491461 (Pubitemid 44057239)
19. L Arias F Armada J Donate J Garcia-Arumi J Giralt B Pazos A Pinero F Martinez JJ Mondejar I Ortega G Zlateva R Buggage 2008 Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss Eye 23 326 333 10.1038/sj.eye.6703053 18202712
20. Tablas de supervivencia de la población española. Instituto Nacional de Estadística [National Statistics Institute]. Available at: http://www.ine.es/jaxi/tabla.do?path=/t20/p319a/1992-2005/l0/&file=01001. px&type=pcaxis. Accesed: 4th of June 2009
21. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G (2005) Economic evaluation using decision analytic modelling. In: Methods for the economic evaluation of health care programmes, 3rd ed. Oxford University Press, Oxford, pp 277-314
22. AF Cruess G Zlateva X Xu G Soubrane D Pauleikhoff A Lotery J Mones R Buggage C Schaefer T Knight TF Goss 2008 Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study Pharmacoeconomics 26 57 73 10.2165/00019053-200826010-00006 18088159
23. Pesos españoles y coste SNS. Año 2005. Ministerio de Sanidad y Consumo. [Health Ministry]. Available at: http://www.msc.es. Accesed: 26th december 2008
24. Indice de precios de consumo. Instituto Nacional de Estadística [National Statistics Institute]. Available at: http://www.ine.es/daco/ipc.htm. Accesed: 4th june 2009
25. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G (2005) Basic types of economic evaluation. In: Methods for the economic evaluation of health care programmes, 3rd ed. Oxford University Press, Oxford, pp 7-26
26. GC Brown S Sharma MM Brown J Kistler 2000 Utility values and age-related macular degeneration Arch Ophthalmol 118 47 51 1:STN:280:DC%2BD3c7gtVelug%3D%3D 10636413
27. NICE. Guide to the methods of technology appraisal, june 2008. Available at: http://www.nice.org.uk. Accesed: 26th december 2008
28. AH Briggs 2000 Handling uncertainty in cost-effectiveness models Pharmacoeconomics 17 479 500 10.2165/00019053-200017050-00006 1:STN:280:DC%2BD3M%2FgsV2msQ%3D%3D 10977389
29. E Mills D Heels-Ansdell S Kelly G Guyatt 2007 A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects J Clin Epidemiol 60 456 460 10.1016/j.jclinepi.2006.09.001 17419956 (Pubitemid 46529143)
30. AE Fung GA Lalwani PJ Rosenfeld SR Dubovy S Michels WJ Feuer CA Puliafito JL Davis HW Flynn Jr M Esquiabro 2007 An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 566 583 10.1016/j.ajo.2007.01.028 1:CAS:528:DC%2BD2sXjsVWitb8%3D 17386270 (Pubitemid 46452533)
31. Rosenfeld PJ (2007) Ranibizumab: The Pronto study. American Academy of Ophthalmology. New Orleans, 10-13th November 2007
32. PA Quiram TS Hassan GA Williams 2007 Treatment of naive lesions in neovascular age-related macular degeneration with pegaptanib Retina 27 851 856 10.1097/IAE.0b013e31806458f0 17891008 (Pubitemid 47479379)
33. S Birch A Gafni 2006 Information created to evade reality (ICER): things we should not look to for answers Pharmacoeconomics 24 1121 1131 10.2165/00019053-200624110-00008 17067196
34. C McCabe K Claxton AJ Culyer 2008 The NICE cost-effectiveness threshold: what it is and what that means Pharmacoeconomics 26 733 744 10.2165/00019053- 200826090-00004 18767894
35. J Soto Alvarez 2004 New drugs in Spain - when are they to be considered cost-effective alternatives and profitable investments for the National Health System? Farm Hosp 28 299 304 1:STN:280:DC%2BD2cvmtFejsw%3D%3D 15369442 [In Spanish]
36. DM Brown CD Regillo 2007 Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients Am J Ophthalmol 144 627 637 10.1016/j.ajo.2007. 06.039 1:CAS:528:DC%2BD2sXhtVOisL7L 17893015 (Pubitemid 47429633)
37. RB Bhisitkul 2006 Vascular endothelial growth factor biology: clinical implications for ocular treatments Br J Ophthalmol 90 1542 1547 10.1136/bjo.2006.098426 1:STN:280:DC%2BD28nnsVynsg%3D%3D 17114590 (Pubitemid 44862578)
38. M Drummond M Sculpher 2005 Common methodological flaws in economic evaluations Med Care 43 5 14 10.1097/01.mlr.0000170001.10393.b7 16056003
39. J Raftery A Clegg J Jones SC Tan A Lotery 2007 Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness Br J Ophthalmol 91 1244 1246 10.1136/bjo.2007.116616 17431015 (Pubitemid 47344908)